<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01460979</url>
  </required_header>
  <id_info>
    <org_study_id>AGO-GYN 8</org_study_id>
    <nct_id>NCT01460979</nct_id>
  </id_info>
  <brief_title>Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma</brief_title>
  <official_title>Activity, Tolerability, Safety of Temsirolimus in Women With Ovarian Cancer Who Progressed During Previous Platinum Chemotherapy or Within 6 Months After Therapy or Advanced Endometrial Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AGO Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AGO Study Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the activity, tolerability and safety of&#xD;
      Temsirolimus in women with ovarian cancer who progressed during the previous platinum&#xD;
      chemotherapy alternatively within 6 months from completion of therapy or advanced endometrial&#xD;
      carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>after 4 months for ovarian cancer and 6 months for endometrial carcinoma after study entry</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>rate and duration of stable diseases according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 and Gynecologic Cancer Intergroup (GCIG)-criteria for ovarian cancer</measure>
    <time_frame>every 8 weeks until progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival according to RECIST 1.1 and cancer antigen 125 (CA 125) (for ovarian cancer) (biological progression-free survival (PFSbio))</measure>
    <time_frame>every 8 weeks until progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>weekly until progression; thereafter every 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety and toxicity, i.e. type, frequency, severity and duration of adverse reactions</measure>
    <time_frame>weekly until progression; thereafter every 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life according to European Organisation for Research and Treatment of Cancer (EORTC) questionaires &quot;QLQ C30&quot;, &quot;QLQ OV28&quot; and &quot;QLQ-EN24&quot;</measure>
    <time_frame>every 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate and duration of stable diseases according to RECIST-criteria for endometrial cancer</measure>
    <time_frame>every 8 weeks until progression</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Genital Diseases, Female</condition>
  <condition>Ovarian Diseases</condition>
  <condition>Ovarian Neoplasms</condition>
  <condition>Endometrial Neoplasms</condition>
  <arm_group>
    <arm_group_label>Temsirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temsirolimus</intervention_name>
    <description>25mg weekly intravenous until progression</description>
    <arm_group_label>Temsirolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women ≥ 18 years&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2&#xD;
&#xD;
          -  Before performance of study specific actions or assessment the patient has to be&#xD;
             informed, has signed the written consent and is willing to follow the requirements&#xD;
             concerning treatment and follow-up.Comment: Procedures which are according to common&#xD;
             clinical routine and having been performed before having given written informed&#xD;
             consent may be used for the purpose of screening procedures or initial medical&#xD;
             assessment as long as these procedures follow the protocol.&#xD;
&#xD;
          -  Required: negative pregnancy test in fertile women&#xD;
&#xD;
        Stratum A - Ovarian Cancer:&#xD;
&#xD;
          -  Histologically confirmed Ovarian Cancer&#xD;
&#xD;
          -  Platin-refractory relapsed disease: progression within a platin-based chemotherapy or&#xD;
             within 6 months after completion of a platin-based chemotherapy&#xD;
&#xD;
          -  Prior treatment with a taxane-based scheme&#xD;
&#xD;
          -  minimum of one measurable or non-measurable tumor lesion(according to RECIST 1.1&#xD;
             criteria)&#xD;
&#xD;
          -  Not more than 2 previous chemotherapies or cytostatic therapies (i.e. monoclonal&#xD;
             antibodies, cytokines, signal transduction inhibitors)&#xD;
&#xD;
        Stratum B - Endometrian Cancer:&#xD;
&#xD;
          -  Histologically confirmed Endometrian Cancer&#xD;
&#xD;
          -  Advanced (International Federation of Gynaecology and Obstetrics (FIGO) III or IV) or&#xD;
             relapsed diseases not amenable to potentially curative treatment with local surgery&#xD;
             and/or radiation therapy&#xD;
&#xD;
          -  Prior endocrine therapy is allowed&#xD;
&#xD;
          -  Prior adjuvant chemotherapy is allowed&#xD;
&#xD;
          -  Minimum of one measurable or non-measurable tumor lesion(according to RECIST 1.1&#xD;
             criteria)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ECOG &gt; 2&#xD;
&#xD;
          -  Prior therapy with mammalian target of rapamycin (mTOR) -Inhibitor&#xD;
&#xD;
          -  Cytostatic therapy (i.e. monoclonal antibodies, cytokines, signal transduction&#xD;
             inhibitors), cytotoxical chemotherapy or endocrine therapy or radiation at the same&#xD;
             time&#xD;
&#xD;
          -  Current or recent treatment with another study drug and/or participation in another&#xD;
             clinical study within 28 days prior to first dose of study treatment&#xD;
&#xD;
          -  Chemotherapy or cytostatic therapy (i.e. monoclonal antibodies, cytokines, signal&#xD;
             transduction inhibitors) or radiation within 28 days prior to start of study treatment&#xD;
&#xD;
          -  Known or supposed hypersensitivity compared to study medication&#xD;
&#xD;
          -  Acute or chronical infection&#xD;
&#xD;
          -  Second malignancy which influences the prognosis of the patient&#xD;
&#xD;
          -  Inadequate renal function (Creatinin &gt; 1.5 x Upper Limit of Normal (ULN))&#xD;
&#xD;
          -  Inadequate liver function (aspartate transaminase (AST), alanine transaminase (ALT),&#xD;
             gamma-Glutamyl transpeptidase (GGT) &gt; 2.5 x ULN or &gt; 5.0 x ULN in the presence of&#xD;
             liver metastasis; Bilirubin &gt; 1.5 x ULN)&#xD;
&#xD;
          -  Platelets &lt; 100.000 /μl; Absolute Neutrophil Count (ANC) &lt; 1.500 /μl&#xD;
&#xD;
          -  Cachectic patients with weight &lt; 45kg&#xD;
&#xD;
          -  Patients who need parenteral nutrition&#xD;
&#xD;
          -  Patients with ileus within the last 28 days&#xD;
&#xD;
          -  One of the following diseases within 12 months prior to first study treatment:&#xD;
             myocardial infarction, severe/unstable angina, bypass surgery of the coronar- or&#xD;
             peripheral vessels, symptomatic heart insufficiency, cerebrovascular insult, transient&#xD;
             ischemic attack (TIA), pulmonary embolism, deep venous thrombosis, other&#xD;
             thromboembolic events&#xD;
&#xD;
          -  Current treatment with Cytochrome P450 3A4 (CYP3A4) -Inhibitors (i.e. protease&#xD;
             inhibitors, antimycotics, calcium channel blocker, macrolide antibiotics, Cimetidine)&#xD;
             or -inductors (i.e. Carbamazepin, Phenobarbital, Phenytoin, Rifampicin, amber)&#xD;
&#xD;
          -  Uncontrolled hypertension (&gt; 150/100 mmHg despite optimal medicinal treatment)&#xD;
&#xD;
          -  Current cardiac arrhythmias (Common Terminology Criteria for Adverse Events of&#xD;
             National Cancer Institute (NCI CTCAE) grade ≥ 2), atrial fibrillation, prolongation of&#xD;
             QTc &gt; 470 msec&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) ≤ 50% defined by echocardiogram&#xD;
&#xD;
          -  NCI CTCAE grade 3 hemorrhage within 4 weeks prior to beginning of treatment&#xD;
&#xD;
          -  Symptoms which indicate brain metastases, spinal cord compression or give new&#xD;
             indications for brain- or leptomeningeal metastases&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) positive or manifested Acquired Immune Deficiency&#xD;
             Syndrome (AIDS-disease)&#xD;
&#xD;
          -  Patients with other severe diseases who represent an inadequate risk for study&#xD;
             participation&#xD;
&#xD;
        Applicable only for patients with no hysterectomy and/or bilateral adnexectomy prior to&#xD;
        start of study.&#xD;
&#xD;
          -  lactation&#xD;
&#xD;
          -  potential fertile women without adequate contraception (potential fertile women must&#xD;
             use one of the following adequate contraception: complete abstinence, intrauterine&#xD;
             spiral or another method with a failure quote &lt; 1% per year)&#xD;
&#xD;
          -  life expectancy &lt; 3 months&#xD;
&#xD;
          -  neurological or psychiatric diseases or drugs or alcohol abuse which suppose no&#xD;
             adequate comprehension and consequently no effective consent to study participation or&#xD;
             no acceptable compliance during the study&#xD;
&#xD;
          -  predictable problems with the compliance to appointments for examinations&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Günter Emons, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>AGO Study Group (Study Group of the Arbeitsgemeinschaft Gynaekologische Onkologie)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Erlangen-Nürnberg</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der Technischen Universität</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der J. W. Goethe-Universität</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen-Marburg, Standort Marburg</name>
      <address>
        <city>Marburg</city>
        <state>Hessen</state>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Offenbach</name>
      <address>
        <city>Offenbach</city>
        <state>Hessen</state>
        <zip>63069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Greifswald der Ernst-Moritz-Arndt-Universität</name>
      <address>
        <city>Greifswald</city>
        <state>Mecklenburg Vorpommern</state>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Göttingen, Georg-August-Universität</name>
      <address>
        <city>Göttingen</city>
        <state>Niedersachsen</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gynäkologisch-onkologische Praxis</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30177</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen Mitte, Evang. Huyssens Stiftung/Knappschaft GmbH</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städt. Klinikum Solingen gGmbH</name>
      <address>
        <city>Solingen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>42653</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité, Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GYNAEKOLOGICUM Bremen</name>
      <address>
        <city>Bremen</city>
        <zip>28211</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/26731724</url>
    <description>Final publication</description>
  </link>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>October 25, 2011</study_first_submitted>
  <study_first_submitted_qc>October 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2011</study_first_posted>
  <last_update_submitted>February 26, 2016</last_update_submitted>
  <last_update_submitted_qc>February 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Endometrial Carcinoma</keyword>
  <keyword>Temsirolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Ovarian Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

